Sirius Therapeutics Secures Nearly $1 Billion Deal for Long-Acting siRNA Therapy SRSD107 with CRISPR Therapeutics

May 20, 2025 14:07 CST Updated 14:07

Sirius Therapeutics

Oligonucleotide Drug Developer

CRISPR Therapeutics

Gene Editing Drug Developer

May 20,Sirius Therapeutics and CRISPR Therapeutics Announce Strategic Partnership to AdvancesiRNA TherapySRSD107 The co-development and commercialization process,Total transaction amount exceeds $8.95 billion。

Source:Sirius Therapeutics Official WeChat

According to the terms of the agreement,Sirius Therapeutics will obtain $95 millionCash and Cash Equivalents as Down Payment, and is eligible to receiveOver 800 Million USDThe upfront and milestone payments. The two parties will jointly develop SRSD107 with a 50:50 cost and profit sharing mechanism. In addition, CRISPR Therapeutics has the priority right to exclusively license up to two additional siRNA projects in the future.

SRSD107 is a new generation ofLong-acting siRNA Therapy, aimed at selectively inhibiting coagulation factor XI（FXI）The FXI target plays a crucial role in pathological thrombosis but has minimal impact on normal hemostatic function. By targeting FXI, SRSD107 is expected to reduce thrombotic events while significantly decreasing the risk of bleeding, demonstrating a distinction from Factor X activity.（FXa）Therapeutic Advantages of Inhibitors. The potential indications for SRSD107 are broad, including atrial fibrillation and venous thromboembolism.（VTE）, cancer-associated thrombosis, end-stage renal disease patients undergoing hemodialysis, and major orthopedic surgery populations with bleeding risks that limit existing treatment options.

Currently, SRSD107 has completed two Phase I clinical trials, showing good safety and tolerability in single-dose administration. Relevant research findings have been presented at the 2025 American College of Cardiology.（ACC）Presented at the Annual Meeting and the 2024 American Society of Hematology (ASH) Annual Meeting. The Phase II clinical trial of SRSD107 is being initiated to evaluate its efficacy in preventing venous thromboembolism in patients undergoing knee replacement surgery.（VTE）Safety and efficacy. This study will provide clinical scientific evidence for confirming its anticoagulant clinical benefits and dose selection for subsequent pivotal trials.

Cover Source:ZCOOL Hello

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn